Drug Profile

BA 102

Alternative Names: BA-102

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroNOS
Class Neuropsychotherapeutics; Small molecules
Mechanism of Action Nitric oxide modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Telomeric 22q13 Monosomy Syndrome
New Molecular Entity Yes

Highest Development Phases

Preclinical Autism spectrum disorder

Most Recent Events

21 Apr 2025 BA 102 receives Orphan Drug status for Autism spectrum disorder in USA
15 Apr 2025 NeuroNOS plans a phase I trial for Autism spectrum disorder in the US by the end of 2026
15 Apr 2025 NeuroNOS plans to file an IND application for the initiation of phase I trial in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com